9 - 10 July 2020

MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases( Time Zone - EASTERN STANDARD TIME (EST)

New medicine for orphan and Rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.

MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases scheduled to be held on 9th -10th July 2020 will provide valuable and necessary platform for uplifting knowledge at the forefront of drug analysis. Over the course of the conference, internationally-renowned speakers can describe how their analysis journeys have developed the response towards up to date challenges. The attending specialists and trade partners will offer an incredible networking expertise.

 

This conference will gather scientists, researchers, entrepreneurs, academicians, medical officers, CEO’s, CSO’s and technologists from everywhere around the globe to discuss on the newest scientific advances within the field of rare diseases & orphan drugs that facilitate to form current and future challenges in drug analysis.

WHAT TO EXPECT
Who should attend?
  • C-Level Executives, VPs/Directors, Heads, Professors, Associate professors (Biology, Biochemistry), Researchers from Pharma/Therapeutics / Biopharma and Universities- Rare diseases department
  • Patient Advocacy groups
Why attend Virtual?
  • 100+ C-level executives, Directors/VPs, Heads experts working on rare disease attending the event
  • Participate in constructive discussion with leading industry experts and decision-makers from pharmaceutical manufacturers who will tackle the most important issues in Rare disease diagnosis.
  • Best opportunity to showcase your work and research in front of industry leaders.
  • Develop your skills by learning new competencies and acquire knowledge from pioneers all around the world.
CONFERENCE AGENDA
CHALLENGES AND OPPORTUNITIES IN TREATMENT OF RARE DISEASES
PROGRESS TOWARDS FIGHTING RARE DISEASES
CONFERENCE SPEAKERS
Speakers
Scott Schliebner

Scott Schliebner

Senior Vice President, Center for Rare Diseases
PRA Health Sciences

Scott Schliebner

Senior Vice President, Center for Rare Diseases
PRA Health Sciences
Karen Frascello

Karen Frascello

Director, Global Medical Affairs, Early Access
Alnylam Pharmaceuticals

Karen Frascello

Director, Global Medical Affairs, Early Access
Alnylam Pharmaceuticals
Dan Donovan

Dan Donovan

Founder & CEO
rareLife solutions

Dan Donovan

Founder & CEO
rareLife solutions
Dr. Michal Konstacky MD, PhD, MBA

Dr. Michal Konstacky MD, PhD, MBA

Global Medical Lead SHP 647
Shire Pharmaceuticals

Dr. Michal Konstacky MD, PhD, MBA

Global Medical Lead SHP 647
Shire Pharmaceuticals
Stavros Ntogiakos

Stavros Ntogiakos

Regional Head of Rare Ocular Disease
Novartis

Stavros Ntogiakos

Regional Head of Rare Ocular Disease
Novartis
Pedro Lendinez Ortega

Pedro Lendinez Ortega

Key Account Manager
en Recordati Rare Diseases

Pedro Lendinez Ortega

Key Account Manager
en Recordati Rare Diseases
Stephen Groft

Stephen Groft

Senior Advisor to the Director NCATS,
NIH

Stephen Groft

Senior Advisor to the Director NCATS,
NIH
John Lagus

John Lagus

Managing Director of Business Development
Tanner Pharma Group

John Lagus

Managing Director of Business Development
Tanner Pharma Group
SPONSORS
Sponsors & Exhibitors
example-image

PRA Health Sciences

example-image

PSR

Speaking Partner
example-image

Comradis

Primary Partner
example-image

Clinigen

Conference Partner
example-image

rareLife solutions

PARTNERS
Media Partners
example-image

Hopkins Biotech Affinity Club

PAST EVENT GALLERY